<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8174">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03000530</url>
  </required_header>
  <id_info>
    <org_study_id>217-MDD-201</org_study_id>
    <nct_id>NCT03000530</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate SAGE-217 in Subjects With Moderate to Severe Major Depressive Disorder</brief_title>
  <official_title>A Phase 2, Two-Part (Open-Label Followed by Double-Blind) Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in the Treatment of Adult Subjects With Moderate to Severe Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sage Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sage Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two-part (open-label followed by double-blind) study evaluating the safety,
      tolerability, pharmacokinetics, and efficacy of SAGE-217 in up to 62 subjects diagnosed with
      moderate to severe Major Depressive Disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part A of the study is an open-label design with dosing of SAGE-217 for 14 days.

      Part B of the study is a randomized, double-blind, parallel-group, placebo-controlled
      design. Eligible subjects will be randomized to SAGE-217 or placebo for 14 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability, as assessed by adverse events [Parts A and B]</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability, as assessed by clinical laboratory measures [Parts A and B]</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability, as assessed by vital signs [Parts A and B]</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability, as assessed by electrocardiograms (ECGs) [Parts A and B]</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability, as assessed by suicidal ideation using the Columbia-Suicide Severity Rating Scale (C-SSRS) [Parts A and B]</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effect of treatment with SAGE-217 compared to placebo on depressive symptoms in patients with Major Depressive Disorder as assessed by the Hamilton Rating Scale for Depression (HAM-D) total score [Parts A and B]</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Major Depression</condition>
  <arm_group>
    <arm_group_label>SAGE-217 dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAGE-217</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAGE-217</intervention_name>
    <arm_group_label>SAGE-217 dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a diagnosis of Major Depressive Disorder that has been present for at
             least a 4-week period as diagnosed by Structured Clinical Interview for DSM-IV Axis I
             Disorders (SCID-I)

        Exclusion Criteria:

          -  Subject has a history of suicide attempt

          -  Subject has a history of treatment-resistant depression, defined as persistent
             depressive symptoms despite treatment with adequate doses of antidepressants from two
             different classes for an adequate amount of time

          -  Active psychosis

          -  Medical history of seizures

          -  Medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Nomikos, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sage Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Handan Gunduz-Bruce, MD, MBA</last_name>
    <phone>203-500-9240</phone>
    <email>handan.gunduz-bruce@sagerx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sage Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrialsinquiry@sagerx.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sagerx.com</url>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 1, 2017</lastchanged_date>
  <firstreceived_date>December 14, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
